---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-024358"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:27:25.523652+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Organon Q4 revenue $1.60B (+8% YoY); FY23 EPS $3.99; FY24 guidance $6.2-6.5B

## Summary
- FY23 revenue $6.3B (+1% as-reported, +3% constant currency).
- FY23 diluted EPS $3.99, non-GAAP adjusted diluted EPS $4.14; Adj. EBITDA $1.9B (31% margin).
- Q4 revenue $1.60B (+8% YoY); Q4 non-GAAP adj. diluted EPS $0.88 (+9%).
- Biosimilars rev +49% (Hadlima >doubled); Women's Health +7% (Follistim +63% ex-FX).
- FY2024 guidance: revenue $6.2-6.5B, Adj. EBITDA margin 31-33%.

## SEC filing metadata
- accession: 0001104659-24-024358
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/0001104659-24-024358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/tm246328d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-024358
- JSON: https://secwatch.observer/filing/0001104659-24-024358.json
- Plain text: https://secwatch.observer/filing/0001104659-24-024358.txt

## Key facts
- Earnings Releases
  Organon & Co. updated its the quarter and full year ended December 31, 2023 guidance (reaffirmed).
  - Period: the quarter and full year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 15, 2024, Organon & Co. (the “ Company ”) issued a press release (the “ Earnings Release ”) regarding its results for the quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1821825/000110465924024358/0001104659-24-024358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.